Clinical Trial

Insulin Intratympanic Application

Completed Early Phase 1
View on ClinicalTrials.gov →
Summary
The objective of the present study was to study the impact of insulin insitu-gel formulation on healing progress after surgical procedures for treatment of dry tympanic membrane perforation for at least three consecutive months. At the beginning, an insulin insitu-gel was prepared from three different polymers compatible with insulin physiochemically and reported to be vain on insulin efficacy or safety. Insulin insitu-gel was prepared using chitosan, polyvinyl alcohol, and Pluronic F127 with glycerol as a penetration enhancer. Selection of an optimized formulation through in situ gel characterization and in vitro drug release kinetics then the formulation was evaluated for healing efficacy on human volunteers in RCT. A randomized controlled clinical study was implemented for clinical evaluation of insitu-gel formulation activity in the Department of Otorhinolaryngology, Minia University Hospital, from January 2025 to March 2026. Perforation healing signs as a primary indicator was followed and reported in three follow-up visits (1 week, 1 month, and 2 months) in addition hearing score pre- and post-surgery as secondary outcomes. Results of a clinical study showed that the healing is significantly superior in the insulin group than in the control group
Protocol Amendment History 2 changes
critical Trial status changed: Enrolling by Invitation → Completed 2026-06-17
notable Enrollment increased: 25 -> 50 participants 2026-06-17
Trial Details
NCT Number NCT07535827
Lead Sponsor Deraya University
Conditions Tympanic Membrane Perforation
Enrollment 50 participants
Start Date 2026-03-20
Primary Completion 2026-05-15 (estimated)
Study Completion 2026-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-16